Cargando…

PB1910: TELAGLENASTAT (CB-839) IN MONOTHERAPY AND IN COMBINATION WITH EPIGENETIC MODULATORS OR IBRUTINIB INDUCES CELL DEATH IN CHRONIC LYMPHOCYTIC LEUKEMIA CELLS

Detalles Bibliográficos
Autores principales:	Jorge, Joana, Santiago, Hugo, Constantino, Beatriz, Costa, Maria Inês, Lapa, Beatriz, Alves, Raquel, Gonçalves, Ana Cristina, Sarmento-Ribeiro, Ana Bela
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2023
Materias:	Publication Only
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10430200/ http://dx.doi.org/10.1097/01.HS9.0000974464.43395.a0

Ejemplares similares

PB1908: NRF2 INHIBITION IN COMBINATION WITH IBRUTINIB IN THE TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA– AN IN VITRO STUDY
por: Jorge, Joana, et al.
Publicado: (2023)

CD133-Functionalized Gold Nanoparticles as a Carrier Platform for Telaglenastat (CB-839) against Tumor Stem Cells
por: Poonaki, Elham, et al.
Publicado: (2022)

PB1719: NIRAPARIB IN B-CELL LYMPHOID MALIGNANCIES: EXPLORING SYNTHETIC LETHALITY AS TARGET FOR THERAPY
por: Lapa, Beatriz, et al.
Publicado: (2023)

PB1822: INHIBITION OF THE DNA DAMAGE RESPONSE: A POSSIBLE NEW ROUTE IN ACUTE MYELOBLASTIC LEUKEMIA TREATMENT
por: Lapa, Beatriz, et al.
Publicado: (2023)

PB2072: EFFICACY AND SIDE EFFECTS OF IBRUTINIB IN RELAPSED AND REFRACTORY MANTLE CELL LYMPHOMA
por: Basturk, A., et al.
Publicado: (2022)

PB1910: CHRONIC MYELOID LEUKEMIA AND RELATIONSHIP TO SECONDARY SOLID NEOPLASMS
por: Ramos, M. J., et al.
Publicado: (2022)

PB2074: IBRUTINIB AS A PROMISING TREATMENT FOR WALDENSTRÖM MACROGLOBULINEMIA
por: Ilhan, O., et al.
Publicado: (2022)

Augmented Therapeutic Potential of Glutaminase Inhibitor CB839 in Glioblastoma Stem Cells Using Gold Nanoparticle Delivery
por: Giesen, Beatriz, et al.
Publicado: (2021)

Glutaminase inhibitor CB-839 synergizes with carfilzomib in resistant multiple myeloma cells
por: Thompson, Ravyn M., et al.
Publicado: (2017)

Metabolic Adjustments following Glutaminase Inhibition by CB-839 in Glioblastoma Cell Lines
por: De los Santos-Jiménez, Juan, et al.
Publicado: (2023)

PB1841: NUCLEOLIN INTERACTS WITH NUCLEOPHOSMIN AS A PREDICTOR OF PROGNOSIS IN ACUTE MYELOBLASTIC LEUKEMIA
por: Pereira, Marta, et al.
Publicado: (2023)

PB1940: REAL-LIFE EXPERIENCE OF THE IMMUNE RECONSTITUTION IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKAEMIA AND SMALL LYMPHOCYTIC LYMPHOMA TREATED WITH IBRUTINIB.
por: Pérez, Belén Olivares, et al.
Publicado: (2023)

PB1781: THERAPEUTIC POTENTIAL OF DNA DAMAGE RESPONSE IN ACUTE MYELOBLASTIC LEUKEMIA
por: Lapa, B., et al.
Publicado: (2022)

PB1958: IBRUTINIB AS THIRD LINE THERAPY IN CLL PATIENTS, A 5-YEAR STUDY IN ALBANIA
por: Qerama, Shaqir, et al.
Publicado: (2023)

PB1782: ZINC IN THE MODULATION OF THE ANTIPROLIFERATIVE AND CYTOTOXIC EFFECTS OF OLAPARIB IN ACUTE MYELOID LEUKEMIA
por: Costa, M. I., et al.
Publicado: (2022)

PB2081: TREATMENT PERSISTENCE AND ADHERENCE TO IBRUTINIB IN PATIENTS WITH WALDENSTRÖM MACROGLOBULINEMIA: A GERMAN CLAIMS DATA ANALYSIS
por: Buske, C., et al.
Publicado: (2022)

PB1856: DEMETHYLATING AGENTS AND HISTONE DEACETYLASE INHIBITORS AS NEW THERAPEUTIC STRATEGIES IN CHRONIC LYMPHOCYTIC LEUKEMIA
por: Jorge #, J., et al.
Publicado: (2022)

PB1879: OVERALL SURVIVAL OF RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS TREATED WITH IBRUTINIB IN ALBANIA (2018-2022)
por: Calliku, E., et al.
Publicado: (2022)

PB1874: BTK GENE MUTATIONS IN RUSSIAN PATIENTS TREATED WITH IBRUTINIB: AS-PCR VERSUS NGS FOR ALLELIC LOAD ASSESSMENT
por: Likold, E., et al.
Publicado: (2022)

PB1881: IBRUTINIB REDUCES THE RISK OF RICHTER’S TRANSFORMATION IN PREVIOUSLY TREATED CLL PATIENTS: A POPULATION-BASED STUDY IN BRITISH COLUMBIA
por: Ramadan, R., et al.
Publicado: (2022)

Preclinical investigations of the efficacy of the glutaminase inhibitor CB-839 alone and in combinations in chronic lymphocytic leukemia
por: Timofeeva, Natalia, et al.
Publicado: (2023)

PB1922: THE FIRST REPORT OF REAL-WORLD OUTCOMES OF ZANUBRUTINIB MONOTHERAPY IN CHRONIC LYMPHOCYTIC LEUKEMIA
por: Luo, Jing, et al.
Publicado: (2023)

PB2349: A PHASE 1, OPEN-LABEL, MULTICENTER, DOSE-ESCALATION STUDY OF SGR-1505 AS MONOTHERAPY IN SUBJECTS WITH MATURE B-CELL MALIGNANCIES
por: Olszewski, Adam, et al.
Publicado: (2023)

DDRE-01. METABOLIC PLASTICITY AND HETEROGENEITY IN IDH1MUT CELL LINES PRODUCES RESISTANCE TO GLUTAMINASE INHIBITION BY CB839
por: Larion, Mioara, et al.
Publicado: (2021)

PB2382: EFFECTS OF ANTIFASCIN COMPOUNDS AGAINST LYMPHOMA CELLS IN VITRO
por: María Hurtado López, Ana, et al.
Publicado: (2023)

PB2510: CHARACTERISATION OF SICKLE CELL DISEASE PATIENTS: A PORTUGUESE REAL-WORLD STUDY (ASCEND)
por: Deveza, Maria Manuel, et al.
Publicado: (2023)

PB1924: INCIDENCE OF CARDIOVASCULAR AND BLEEDING EVENTS IN CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS (CLL) TREATED WITH IBRUTINIB – A RETROSPECTIVE ANALYSIS ON CONSECUTIVE PATIENTS FROM A WELL-DEFINED REGION.
por: Andersson, Maria, et al.
Publicado: (2023)

Massive dissemination of a SARS-CoV-2 Spike Y839 variant in Portugal
por: Borges, Vítor, et al.
Publicado: (2020)

Zinc Prevents DNA Damage in Normal Cells but Shows Genotoxic and Cytotoxic Effects in Acute Myeloid Leukemia Cells
por: Costa, Maria Inês, et al.
Publicado: (2022)

PB2335: BURDEN OF HOSPITALIZATION, COSTS AND CO-MORBIDITIES IN MEDICAID PATIENTS WITH SICKLE CELL DISEASE (SCD): ANALYSIS OF NATIONAL IN-PATIENT HOSPITAL DATABASE
por: Aggarwal, S., et al.
Publicado: (2022)

PB2005: AZACITIDINE IN COMBINATION WITH 14-DAY VENETOCLAX VERSUS AZACITIDINE MONOTHERAPY FOR MYELODYSPLASTIC SYNDROME WITH INCREASED BLASTS-2 IN CLINICAL PRACTICE SETTING
por: Žučenka, Andrius, et al.
Publicado: (2023)

PB1878: CROSS-TRIAL ANALYSIS OF FIXED-DURATION IBRUTINIB (I) PLUS VENETOCLAX (V) VS FLUDARABINE (F), CYCLOPHOSPHAMIDE (C), AND RITUXIMAB (R) AS FIRST-LINE TREATMENT FOR CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)
por: Barrientos, J. C., et al.
Publicado: (2022)

Antitumor Effect of Brusatol in Acute Lymphoblastic Leukemia Models Is Triggered by Reactive Oxygen Species Accumulation
por: Jorge, Joana, et al.
Publicado: (2022)

PB2309: EVALUATION OF MORBIMORTALITY FACTORS OF PATIENTS WITH ACQUIRED THROMBOTIC THROMBOCYTOPENIC PURPURA
por: Pinto, M. I., et al.
Publicado: (2022)

PB2701: SAFETY OF 30 MINUTES INFUSION OF RITUXIMAB BIOSIMILAR. A COHORT STUDY.
por: Palomares, Laida Cuevas, et al.
Publicado: (2023)

PB2035: CAMMA 3: A MULTICENTER PHASE IB TRIAL EVALUATING THE SAFETY, PHARMACOKINETICS, AND ACTIVITY OF SUBCUTANEOUS CEVOSTAMAB MONOTHERAPY IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA
por: Delimpasi, S., et al.
Publicado: (2022)

PB2527: COMPARING REAL-LIFE VERSUS PREDICTED PARAMETERS WITH OPTIA SPECTRA IN RED BLOOD CELL EXCHANGE IN SICKLE-CELL DISEASE PATIENTS
por: Rumschisky, Pablo Palomo, et al.
Publicado: (2023)

Workshop 83_9: Setup & Globals
Publicado: (1983)

PB2327: IS THERE ANY VALUE OF GERIATRIC INDICES IN DIFFUSE LARGE B CELL LYMPHOMA OF THE ELDERLY?
por: Dragčević, Dora, et al.
Publicado: (2023)

The glutaminase inhibitor telaglenastat enhances the antitumor activity of signal transduction inhibitors everolimus and cabozantinib in models of renal cell carcinoma
por: Emberley, Ethan, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_tk3asbml4t62ufj12ddl88us2l